thiazoles has been researched along with Androgen-Independent Prostatic Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ban, F; Carlson, ML; Cherkasov, A; Dalal, K; Duong, F; LeBlanc, E; Li, H; Morin, H; Ong, CJ; Peacock, J; Perez, C; Rennie, PS; Roshan-Moniri, M; Sharma, A; Shepherd, A; Tam, KJ | 1 |
| Beumer, JH; Chatta, GS; Chen, CS; Christner, SM; Kraft, AS; Lilly, MB; Mitsuhashi, M; Twardowski, PW; Ye, W | 1 |
| Araujo, JC; Armstrong, AJ; Begbie, S; Bellmunt, J; Cheng, S; de Bono, JS; Durham, S; Efstathiou, E; Gallardo, E; Goebell, PJ; Heidenreich, A; Hong, JH; Logothetis, CJ; Matveev, VB; McCaffrey, J; Morris, MJ; Oudard, S; Paliwal, P; Richardet, E; Saad, F; Serrano, SV; Sizer, B; Trudel, GC; Wilding, G; Yu, EY | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Nambiar, DK; Singh, RP | 1 |
| Alumkal, JJ; Chin, BB; Deng, X; Doot, RK; Duan, F; Febbo, PG; Hartfeil, D; Herman, B; Higano, CS; Mankoff, DA; Muzi, M; Taplin, ME; Taub, JM; Yu, EY | 1 |
| Deng, ZL; Lu, ZJ; Su, J; Wei, YF; Yuan, L; Zhu, C; Zhu, QY | 1 |
| McNaughton, M; Pitman, M; Pitson, SM; Pyne, NJ; Pyne, S | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Tonissi, F | 1 |
4 trial(s) available for thiazoles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Testosterone; Thiazoles; Treatment Outcome | 2013 |
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dasatinib; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Taxoids; Thiazoles; Treatment Failure | 2013 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Bone and Bones; Bone Neoplasms; Dasatinib; Disease-Free Survival; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Receptors, Androgen; Thiazoles; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
5 other study(ies) available for thiazoles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Topics: Amino Acid Sequence; Binding Sites; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Imidazoles; Male; Mutation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Domains; Protein Multimerization; Receptors, Androgen; Sequence Homology, Amino Acid; Small Molecule Libraries; Thiazoles | 2018 |
Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Lipid Metabolism; Male; Metribolone; Molecular Targeted Therapy; Phosphorylation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Silybin; Silymarin; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2; Thiazoles; Transfection | 2014 |
[Indirubin inhibits the proliferation of prostate cancer PC-3 cells].
Topics: Antibiotics, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Cyclin D1; Dose-Response Relationship, Drug; Genes, myc; Humans; Indoles; Male; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-myc; Tetrazolium Salts; Thiazoles | 2015 |
Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
Topics: Adamantane; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Male; Oxidoreductases; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Pyridines; Thiazoles | 2016 |
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Taxoids; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |